Related Experiment Video
Updated: Aug 15, 2026

Mesenteric Artery Contraction and Relaxation Studies Using Automated Wire Myography
Published on: September 22, 2011
Protective effects of calcium antagonists in different organs and tissues
1Department of Pharmacotherapy, Academic Medical Centre, Amsterdam, The Netherlands.
Abstract:
The therapeutic efficacy of calcium antagonists in ischemic disorders of various tissues is attributed to vasodilator and antivasoconstrictor activities. A direct, energy-conserving, antiischemic effect of certain calcium antagonists has been claimed repeatedly by basic scientists. The clinical value of such effects has been doubtful until recently, when the organ-protective activity of certain calcium antagonists was confirmed in a few large-controlled clinical trials. The following evidence has been presented for the protective activity of calcium antagonists: (1) for the heart, beneficial effects of verapamil and diltiazem have been shown on reinfarction and mortality rates, (2) relative to the brain, the beneficial effect of nimodipine has been shown in preventing neurologic deficits after subarachnoidal hemorrhage, and an antimigraine effect of flunarizine has been demonstrated, (3) concerning the blood vessels, israpidine and lacidipine have been demonstrated to have antiatherogenic potency in animal models, and (4) for the kidneys, an antivasoconstrictor effect occurs at the preglomerular level. In addition, verapamil, diltiazem, and nitrendipine may protect against radiocontrast-induced nephrotoxicity, and verapamil counteracts cyclosporine nephrotoxicity.
Insights
Calcium antagonists offer organ protection in ischemic conditions. Clinical trials confirm their benefits for the heart, brain, blood vessels, and kidneys, validating earlier scientific claims.
Area of Science:
- Pharmacology
- Cardiology
- Neurology
- Nephrology
Background:
- Calcium antagonists are known for vasodilator and antivasoconstrictor activities.
- Basic science suggested direct anti-ischemic effects, but clinical value was uncertain.
- Recent large clinical trials have confirmed organ-protective effects.
Purpose of the Study:
- To review the evidence for the organ-protective activity of calcium antagonists.
- To highlight clinical benefits in various tissues.
Main Methods:
- Review of clinical trials and scientific evidence.
- Analysis of data from studies on heart, brain, blood vessels, and kidneys.
Main Results:
- Verapamil and diltiazem reduce reinfarction and mortality rates.
- Nimodipine prevents neurologic deficits post-subarachnoid hemorrhage; flunarizine has antimigraine effects.
- Israpidine and lacidipine show antiatherogenic potential; several agents protect kidneys from toxicity.
Conclusions:
- Calcium antagonists demonstrate significant organ-protective effects in ischemic disorders.
- Clinical evidence supports the use of specific calcium antagonists for treating various conditions.
Related Concept Videos
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Skeleton and Calcium Homeostasis
Synthesis and Functions of Calcitonin
The exact mechanisms by which calcitonin operates in calcium homeostasis remain elusive, but its significance is evident in several vital...
Antihypertensive Drugs: Action of Calcium Channel Blockers
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...

